drugset / Trial / NCT01288430
A Study of DS-2248 in Participants With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase 1 clinical trial is intended to understand the safety and tolerability of a new anticancer drug in subjects with advanced solid tumors. The patients who qualify for the study will receive a once daily dose of the drug taken by mouth and will undergo several tests to measure the drug in the blood and to understand the safety, tolerability and any effect of the drug on the tumor. The antitumor effect of the drug is not known in human.
Timeline
- Start
- 2011-03-29
- Primary completion
- 2014-02-13
- Completion
- 2014-02-13
Outcome
Outcome not reported
Stopped (Business): “The trial was terminated as per Sponsor decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DS-2248 | Small molecule | 1 mg | Oral |
| Subject | DS-2248 | Small molecule | 4.5 mg/m2 | Oral |
| Subject | DS-2248 | Small molecule | 5 mg | Oral |
| Subject | DS-2248 | Small molecule | 20 mg | Oral |
| Subject | DS-2248 | Small molecule | 50 mg | Oral |